1
|
Chai C, Tang H, Miao X, Su Y, Li L, Yu C, Yi J, Ye Z, Miao L, Zhang B, Wang Z, Luo W, Hu J, Zhang H, Zhou W, Xu H. Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line. Hum Cell 2024; 37:1578-1592. [PMID: 39012569 DOI: 10.1007/s13577-024-01100-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 07/03/2024] [Indexed: 07/17/2024]
Abstract
In this study, a novel pancreatic cancer cell line, termed pancreatic ductal adenocarcinoma (PDAC)-X3 cell line, was successfully derived from the primary tumor. Comprehensive analyses of its malignant phenotype, molecular properties, specific biomarkers, and histological features confirmed that PDAC-X3 cells serve as a valuable model for investigating the underlying mechanisms driving pancreatic carcinogenesis and advancing potential therapeutic strategies. The newly established cell line was continuously cultured for over 12 months and was stably passaged through more than 50 generations. Morphologically, PDAC-X3 cells displayed characteristics typical of epithelial tumors. The population doubling time for PDAC-X3 cells was determined to be 50 h. Karyotype analysis revealed that 75% of PDAC-X3 cells presented as hypotriploid, while 25% were sub-tetraploid, with representative karyotypes being 53 and XY der (1) inv (9) der (22). In suspension culture, PDAC-X3 cells efficiently formed organoids. Upon inoculation into BALB/C nude mice, these cells initiated the development of xenograft tumors, achieving a tumor formation rate of 33%. Morphologically, these xenografted tumors closely resembled the primary tumor. Drug sensitivity assays indicated that PDAC-X3 cells exhibited resistance to oxaliplatin but demonstrated sensitivity to 5-Fluorouracil (5-FU), gemcitabine, and paclitaxel. Immunohistochemical analysis revealed that CK7, CK19, E-cadherin, Vimentin, CA19-9 were positively expressed in PDAC-X3 cells. Meanwhile, the expression rate for Ki-67 was 30%, and that for CEA was not detected. Our findings underscore that PDAC-X3 represents a novel pancreatic cancer cell line, positioning it as a valuable model for basic research and the advancement of therapeutic strategies against pancreatic cancer.
Collapse
Affiliation(s)
- Changpeng Chai
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
- The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Huan Tang
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Xin Miao
- The First School of Clinical Medicine, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China
| | - Yuanhui Su
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Lu Li
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
| | - Cheng Yu
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
- Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou, 730000, China
| | - Jianfeng Yi
- The First School of Clinical Medicine,Gansu University of Chinese Medicine, Lanzhou, 730000, China
| | - Zhenzhen Ye
- The First School of Clinical Medicine,Gansu University of Chinese Medicine, Lanzhou, 730000, China
| | - Long Miao
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Bo Zhang
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
| | - Zhengfeng Wang
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
- The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, China
| | - Wei Luo
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
| | - Jinjing Hu
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China
| | - Hui Zhang
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
- Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 730000, China.
| | - Wence Zhou
- The Second Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
- Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, 730000, China.
| | - Hao Xu
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, China.
- The First Clinical Medical School of Lanzhou University, Lanzhou, 730000, China.
- The First School of Clinical Medicine, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
| |
Collapse
|
2
|
Xu H, Chai CP, Tang H, Su YH, Yu C, Li L, Yi JF, Ye ZZ, Wang ZF, Hu JJ, Luo W, Zhang H, Miao X, Zhou WC. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2. World J Oncol 2024; 15:114-125. [PMID: 38274721 PMCID: PMC10807924 DOI: 10.14740/wjon1757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 12/11/2023] [Indexed: 01/27/2024] Open
Abstract
Background Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignant tumor of the biliary tract that is prone to recurrence and metastasis and is characterized by poor sensitivity to chemotherapy and overall prognosis. For these reasons, there is an urgent need to understand its pathological mechanisms and develop effective treatments. To address this challenge, the establishment of suitable preclinical models is critical. Methods Fresh ICC tissue samples were used for primary culture and subculture. The cell line was evaluated by cell proliferation assays, clonal formation assays, karyotype analysis, and short tandem repeat (STR) analysis. Drug resistances against oxaliplatin, paclitaxel, gemcitabine and 5-fluorouracil (5-FU) were evaluated by CCK-8 assay. Subcutaneous injection of 1 × 106 cells to three BALB/c nude mice was conducted for xenograft studies. The hematoxylin and eosin (H&E) staining was used to detect the pathological status of the cell line. The expression of biomarkers CK7, CK19, Ki-67, E-cadherin and vimentin was determined by immunocytochemistry assay. Results A new ICC cell line named ICC-X2 was successfully established. Like ICC-X3 established using the same patient's metastatic tumor, the cell line has been continuously cultured in vitro for more than a year and has been passaged more than 100 times. ICC-X2 retained the typical biliary epithelial morphology. The population doubling time of ICC-X2 is 48 h. The cells demonstrated an abnormal nearly tetraploid karyotype. The STR analysis confirmed that ICC-X2 was highly consistent with the primary tumor tissue and not cross-contaminated by existing cell lines. ICC-X2 cells positively expressed CK7, CK19, E-cadherin, and vimentin, and the positive expression of Ki-67 in ICC-X2 cells was 40%. The ICC-X2 cells exhibited a strong clonogenic ability. The drug sensitivity test indicated that ICC-X2 was sensitive to oxaliplatin and paclitaxel, but naturally resistant to gemcitabine and 5-FU. ICC-X2 was rapidly able to form transplanted tumors in vivo after subcutaneous inoculation in nude mice. Conclusions ICC-X2 is an excellent experimental model that can be used for studying the occurrence, development, and metastasis of ICC and investigating the mechanism of tumor drug resistance.
Collapse
Affiliation(s)
- Hao Xu
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
- The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- These authors contributed equally to this work
| | - Chang Peng Chai
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- These authors contributed equally to this work
| | - Huan Tang
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- These authors contributed equally to this work
| | - Yuan Hui Su
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
| | - Cheng Yu
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou 730000, China
| | - Lu Li
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
| | - Jian Feng Yi
- The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Department of Surgery, The First School of Clinical Medicine of Gansu University of Chinese Medicine, Lanzhou 730000, China
| | - Zhen Zhen Ye
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
| | - Zheng Feng Wang
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
| | - Jin Jing Hu
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
| | - Wei Luo
- The Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China
| | - Hui Zhang
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, China
| | - Xin Miao
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, China
| | - Wen Ce Zhou
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China
- Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, China
| |
Collapse
|
3
|
Xu H, Chai CP, Miao X, Tang H, Hu JJ, Zhang H, Zhou WC. Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1. World J Gastroenterol 2023; 29:2642-2656. [PMID: 37213400 PMCID: PMC10198051 DOI: 10.3748/wjg.v29.i17.2642] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 02/17/2023] [Accepted: 04/13/2023] [Indexed: 05/23/2023] Open
Abstract
BACKGROUND An in-depth study of the pathogenesis and biological characteristics of ampullary carcinoma is necessary to identify appropriate treatment strategies. To date, only eight ampullary cancer cell lines have been reported, and a mixed-type ampullary carcinoma cell line has not yet been reported.
AIM To establish a stable mixed-type ampullary carcinoma cell line originating from Chinese.
METHODS Fresh ampullary cancer tissue samples were used for primary culture and subculture. The cell line was evaluated by cell proliferation assays, clonal formation assays, karyotype analysis, short tandem repeat (STR) analysis and transmission electron microscopy. Drug resistances against oxaliplatin, paclitaxel, gemcitabine and 5-FU were evaluated by cell counting kit-8 assay. Subcutaneous injection 1 × 106 cells to three BALB/c nude mice for xenograft studies. The hematoxylin-eosin staining was used to detect the pathological status of the cell line. The expression of biomarkers cytokeratin 7 (CK7), cytokeratin 20 (CK20), cytokeratin low molecular weight (CKL), Ki67 and carcinoembryonic antigen (CEA) were determined by immunocytochemistry assay.
RESULTS DPC-X1 was continuously cultivated for over a year and stably passaged for more than 80 generations; its population doubling time was 48 h. STR analysis demonstrated that the characteristics of DPC-X1 were highly consistent with those of the patient’s primary tumor. Furthermore, karyotype analysis revealed its abnormal sub-tetraploid karyotype. DPC-X1 could efficiently form organoids in suspension culture. Under the transmission electron microscope, microvilli and pseudopods were observed on the cell surface, and desmosomes were visible between the cells. DPC-X1 cells inoculated into BALB/C nude mice quickly formed transplanted tumors, with a tumor formation rate of 100%. Their pathological characteristics were similar to those of the primary tumor. Moreover, DPC-X1 was sensitive to oxaliplatin and paclitaxel and resistant to gemcitabine and 5-FU. Immunohistochemistry showed that the DPC-X1 cells were strongly positive for CK7, CK20, and CKL; the Ki67 was 50%, and CEA was focally expressed.
CONCLUSION Here, we have constructed a mixed-type ampullary carcinoma cell line that can be used as an effective model for studying the pathogenesis of ampullary carcinoma and drug development.
Collapse
Affiliation(s)
- Hao Xu
- The Forth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Chang-Peng Chai
- The Forth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Xin Miao
- State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, Gansu Province, China
| | - Huan Tang
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Jin-Jing Hu
- The Forth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Hui Zhang
- Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| | - Wen-Ce Zhou
- The Second Clinical Medical College, Lanzhou University, Lanzhou 730000, Gansu Province, China
- Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China
| |
Collapse
|